Heron Therapeutics, Inc. (HRTX): Price and Financial Metrics


Heron Therapeutics, Inc. (HRTX): $9.41

-0.36 (-3.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

HRTX POWR Grades


  • Growth is the dimension where HRTX ranks best; there it ranks ahead of 74.79% of US stocks.
  • The strongest trend for HRTX is in Momentum, which has been heading down over the past 52 weeks.
  • HRTX's current lowest rank is in the Quality metric (where it is better than 7.44% of US stocks).

HRTX Stock Summary

  • HRTX's went public 34.27 years ago, making it older than 91.52% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 562.05%, Heron Therapeutics Inc's debt growth rate surpasses 97.7% of about US stocks.
  • As for revenue growth, note that HRTX's revenue has grown -16.31% over the past 12 months; that beats the revenue growth of merely 11.33% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Heron Therapeutics Inc are MNOV, BLI, ADVM, CCXI, and FREQ.
  • HRTX's SEC filings can be seen here. And to visit Heron Therapeutics Inc's official web site, go to www.herontx.com.

HRTX Valuation Summary

  • In comparison to the median Healthcare stock, HRTX's price/earnings ratio is 113.97% lower, now standing at -5.1.
  • Over the past 243 months, HRTX's EV/EBIT ratio has gone down 11.1.
  • Over the past 243 months, HRTX's EV/EBIT ratio has gone down 11.1.

Below are key valuation metrics over time for HRTX.

Stock Date P/S P/B P/E EV/EBIT
HRTX 2021-08-31 14.3 7.4 -5.1 -4.9
HRTX 2021-08-30 14.3 7.4 -5.1 -4.9
HRTX 2021-08-27 14.2 7.4 -5.0 -4.9
HRTX 2021-08-26 14.1 7.3 -5.0 -4.8
HRTX 2021-08-25 14.3 7.4 -5.1 -4.9
HRTX 2021-08-24 14.1 7.3 -5.0 -4.9

HRTX Growth Metrics

  • Its 3 year price growth rate is now at -2.04%.
  • Its 4 year cash and equivalents growth rate is now at 51.85%.
  • Its 3 year cash and equivalents growth rate is now at -65.51%.
HRTX's revenue has moved up $86,296,000 over the prior 70 months.

The table below shows HRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 86.296 -210.65 -228.318
2021-06-30 83.031 -199.538 -234.138
2021-03-31 83.256 -193.823 -228.313
2020-12-31 88.638 -184.82 -227.278
2020-09-30 103.116 -159.243 -222.917
2020-06-30 125.775 -142.66 -198.284

HRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HRTX has a Quality Grade of D, ranking ahead of 9.05% of graded US stocks.
  • HRTX's asset turnover comes in at 0.243 -- ranking 181st of 682 Pharmaceutical Products stocks.
  • IBIO, COLL, and PTGX are the stocks whose asset turnover ratios are most correlated with HRTX.

The table below shows HRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.243 0.485 -0.993
2021-06-30 0.228 0.515 -1.093
2021-03-31 0.224 0.582 -1.080
2020-12-31 0.214 0.592 -0.933
2020-09-30 0.227 0.586 -0.779
2020-06-30 0.277 0.581 -0.676

HRTX Price Target

For more insight on analysts targets of HRTX, see our HRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.00 Average Broker Recommendation 1.42 (Moderate Buy)

HRTX Stock Price Chart Interactive Chart >

Price chart for HRTX

HRTX Price/Volume Stats

Current price $9.41 52-week high $22.40
Prev. close $9.77 52-week low $9.03
Day low $9.03 Volume 1,981,800
Day high $9.63 Avg. volume 1,391,211
50-day MA $11.01 Dividend yield N/A
200-day MA $13.86 Market Cap 959.21M

Heron Therapeutics, Inc. (HRTX) Company Bio


Heron Therapeutics is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. The company was founded in 1983 and is based in Redwood City, CA.


HRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

HRTX Latest Social Stream


Loading social stream, please wait...

View Full HRTX Social Stream

Latest HRTX News From Around the Web

Below are the latest news stories about Heron Therapeutics Inc that investors may wish to consider to help them evaluate HRTX as an investment opportunity.

Heron Therapeutics to Present at Upcoming Investor Conferences

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Heron management will present and host one-on-one meetings at the following investor conferences.

Yahoo | November 11, 2021

Heron Therapeutics EPS beats by $0.10, misses on revenue

Heron Therapeutics (NASDAQ:HRTX): Q3 GAAP EPS of -$0.51 beats by $0.10. Revenue of $23.23M (+16.3% Y/Y) misses by $2.28M. Shares -1.15%. Press Release As of September 30, 2021, Heron had cash, cash equivalents and short-term investments of $202.8 million, compared to $208.5 million as of December 31, 2020....

Seeking Alpha | November 3, 2021

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 15.00% and -7.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2021

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2021 and highlighted recent corporate updates.

Yahoo | November 3, 2021

Heron Therapeutics (HRTX) Set to Announce Quarterly Earnings on Wednesday

Heron Therapeutics (NASDAQ:HRTX) will be issuing its quarterly earnings data after the market closes on Wednesday, November 3rd. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link. Heron Therapeutics (NASDAQ:HRTX) last released its […]

Dakota Financial News | November 1, 2021

Read More 'HRTX' Stories Here

HRTX Price Returns

1-mo -14.53%
3-mo -19.23%
6-mo -29.46%
1-year -47.69%
3-year -66.45%
5-year -36.20%
YTD -55.54%
2020 -9.94%
2019 -9.41%
2018 43.31%
2017 38.17%
2016 -50.94%

Continue Researching HRTX

Here are a few links from around the web to help you further your research on Heron Therapeutics Inc's stock as an investment opportunity:

Heron Therapeutics Inc (HRTX) Stock Price | Nasdaq
Heron Therapeutics Inc (HRTX) Stock Quote, History and News - Yahoo Finance
Heron Therapeutics Inc (HRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8114 seconds.